Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018081512) COMBINATION OF AN ANTI-VEGFR-2 ANTIBODY AND AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/081512 International Application No.: PCT/US2017/058684
Publication Date: 03.05.2018 International Filing Date: 27.10.2017
IPC:
C07K 16/28 (2006.01) ,C07K 16/30 (2006.01) ,A61K 39/00 (2006.01)
[IPC code unknown for C07K 16/28][IPC code unknown for C07K 16/30][IPC code unknown for A61K 39]
Applicants:
IMCLONE LLC [US/US]; c/o Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285, US
MEDIMMUNE, LTD [GB/GB]; Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH UK, GB
Inventors:
GAYNOR, Richard Brian; US
KARASARIDES, Maria; US
Agent:
GARCIA, Carlos A.; US
BARRETT, Brian P.; US
Priority Data:
62/414,32028.10.2016US
62/460,36617.02.2017US
Title (EN) COMBINATION OF AN ANTI-VEGFR-2 ANTIBODY AND AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCER
(FR) COMBINAISON D'UN ANTICORPS ANTI-VEGFR -2 ET D'UN ANTICORPS ANTI-PD-L1 POUR LE TRAITEMENT DU CANCER
Abstract:
(EN) The present disclosure relates to a combination of anti-human VEGFR-2 antibodies (Ramucirumab) and anti-human PD-L1 (durvalumab) antibodies for treating certain disorders, including advanced gastric or gastroesophageal junction adenocarcinomas, non-small cell lung cancer, and hepatocellular carcinomas. Sequences 3 & 4 represent Ramucirumab VL and VH; Sequences 7 & 8 those of Durvalumab.
(FR) La présente invention concerne une combinaison d'anticorps anti-VEGFR -2 humains (Ramucirumab) et d'anticorps anti-PD-L1 humain (durvalumab) pour le traitement de certains troubles, comprenant des adénocarcinomes avancés de la jonction gastrique ou gastro-œsophagienne, le cancer du poumon non à petites cellules et des carcinomes hépatocellulaires. Les séquences 3 et 4 représentent Ramucirumab VL et VH ; les séquences 7 et 8 sont celles de Durvalumab.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)